Our Contrast Media API production facilities secured cGMP certification.

Ningbo Harvest Polymer Technology Co., Ltd. was acquired to broaden the scope of our business.

Our first EHS audit by a Fortune 500 pharmaceutical company was undertaken and successfully passed.

The company's name was shortened to Zhejiang Haizhou Pharmaceutical Co., Ltd.

The improved waste treatment facility was commissioned.

Maiden clearance from the U.S. FDA was achieved, with a RMB15 million capital injection being approved to upgrade wastewater- and off-gas-treatment systems.

Three new workshops for the production of contrast media intermediates were built.

Zhejiang Jianfeng Haizhou Pharmaceutical Co was designated as a National High-Tech Enterprise; EDQM-approved Guaifenesin API facilities were audited by Wyeth, Johnson & Johnson and Sanofi.

ISO 9001, ISO 14001 and OHSAS 18001 certifications were awarded.

Infrastructure at the Yanhai Industrial Park was extended, with the addition of two multifunctional workshops to improve CMO services.

The production of contrast media intermediates was initiated by Zhejiang Jianfeng Haizhou Pharmaceutical Co.

Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd was acquired by the current shareholders, converting the business from a state-owned enterprise to a private entity. As part of the process, cGMP inspection was passed and the GMP certificate for guaifenesin was awarded.

To meet with the requirements for environmental protection and cater for future expansion, Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd. relocated to the Yanhai Industrial Park, a national-level API production base.

The company was renamed as Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd.

Production of the expectorant guaifenesin was initiated.

The predecessor to our current company, The Linhai Pharmaceutical Factory, was established to manufacture API’s and produce traditional Chinese medicine preparations.